GTC Biotherapeutics (fka GTCB)

[DewDiligence]

Results of Surveys on US ATryn Partnership


Timing of partnership (survey #7):

Q: When will GTC ink a partnership deal for ATryn commercialization and clinical development in the US?

2007: 22%
1H08: 56%
2H08 or later: 12%
Never: 10%


Identity of partner (survey #8)

Q: Who will be GTC’s U.S. ATryn partner?

GENZ 23%
PFE 9%
NVS 8%
NVO 6%
WYE 6%
BAX 4%
Bayer 4%
JNJ 4%
ZGEN 4%
AMGN 2%
DNA 2%
GSK 2%
Shire 2%
SNY 2%
Talecris 2%
Some other company: 9%
Nobody: 8%


Partnership terms (survey #9):

Q1: The amount of up-front money will be:

<$10M: 55%
$10-19M: 39%
$20M or more: 6%

Q2: Cumulative milestones for the HD indication will be:

<$10M: 32%
$10-19M: 48%
$20M or more: 19%

Q3: CLINICAL and REGULATORY milestones for the DIC indication will be:

<$50M: 35%
$50-99M: 42%
$100M or more: 23%

Q4: SALES-based milestones for the DIC indication will be:

<$50M: 16%
$50-99M: 42%
$100M or more: 42%

Q5: The TOTAL amount from the four questions above will be:

<$100M: 13%
$100-249M: 55%
$250M or more: 32%

--
Comments are welcome on any of the above. Thanks to all of the survey participants for participating.